The serum phosphoproteomics study was also executed in GC patient samples to overcome the non-specific diagnosis of gastric cancer with existing carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) biomarkers. This evidence concerns the gene CEACAM5 and gastric cancer.